Analyst Research

Report Title Price
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Ford Investor Services, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nymox Pharmaceutical Corp reports positive update on nerve sparing and sexual function preservation in men treated with NX-1207

Tuesday, 17 Jun 2014 10:00am EDT 

Nymox Pharmaceutical Corp:Says new data supporting positive sexual functional preservation profile of NX-1207, company's lead compound in Phase 3 development for treatment of prostate enlargement (BPH or benign prostatic hyperplasia) and Phase 2 development for localized prostate cancer.Detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage.These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments. 

Company Quote

0.015 +0.98%
4:00pm EDT